Clinical Trial Update: PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib [Phase 1]

View source ↗

Summary

Phase 1 trial update of a combination of PI3 kinase inhibitors and Palbociclib (PIPA) for advanced solid tumors and breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• PI3K inhibitors (PI3K inhibitors)
• Palbociclib (palbociclib)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Advanced Solid Tumours, Breast Cancer | Phase 1 | Status: COMPLETED